Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q3 2016 · 10-Q
Revenue$142.91M$142.91M−13.4% vs Q3 2015 Net Income$21.34M$21.34M−42.2% vs Q3 2015 EPS Diluted$0.45$0.45−43.0% vs Q3 2015 Gross Profit$35,478,000−43.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived$27,076,000−74.2% Free Cash Flowderived$10,079,000−88.9% Margins · derivedGross margin24.8%−13.5 pt vs Q3 2015
Operating margin24.8%−13.5 pt vs Q3 2015
Net margin14.9%−7.5 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 9, 2016 · 40 d after period end